Argent Trust Co Increases Position in Sanofi (NASDAQ:SNY)

Argent Trust Co raised its position in shares of Sanofi (NASDAQ:SNYFree Report) by 13.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,681 shares of the company’s stock after buying an additional 2,845 shares during the quarter. Argent Trust Co’s holdings in Sanofi were worth $1,270,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. SRS Capital Advisors Inc. increased its position in Sanofi by 289.1% during the 1st quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock valued at $25,000 after buying an additional 344 shares in the last quarter. Householder Group Estate & Retirement Specialist LLC purchased a new position in shares of Sanofi in the 3rd quarter worth about $26,000. Indiana Trust & Investment Management CO purchased a new position in shares of Sanofi in the 3rd quarter worth about $27,000. Fairfield Bush & CO. bought a new position in Sanofi in the 1st quarter worth about $26,000. Finally, Eagle Bay Advisors LLC bought a new stake in Sanofi during the 2nd quarter valued at about $28,000. Institutional investors own 10.06% of the company’s stock.

Analysts Set New Price Targets

SNY has been the topic of a number of research reports. Stifel Nicolaus downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. StockNews.com raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, January 9th. JPMorgan Chase & Co. lowered Sanofi from an “overweight” rating to a “neutral” rating in a report on Tuesday, December 5th. Finally, Morgan Stanley initiated coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $57.50.

Get Our Latest Research Report on SNY

Sanofi Stock Down 0.6 %

SNY opened at $46.95 on Tuesday. The company has a market capitalization of $118.76 billion, a PE ratio of 19.89, a price-to-earnings-growth ratio of 2.24 and a beta of 0.63. The firm has a 50-day simple moving average of $49.26 and a two-hundred day simple moving average of $50.77. The company has a quick ratio of 0.38, a current ratio of 1.28 and a debt-to-equity ratio of 0.19. Sanofi has a 52 week low of $42.63 and a 52 week high of $57.82.

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Recommended Stories

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.